

Specialty Infusion Services	∠ \ TM				
		PREVIOUS ADM	MINISTRATIO	ON	
Please provide the follo	wing information:	ast Infusion Date:		Next Infusion Date:	
		Patient Info			
Patient Name:	DOB: _			ght: Weight:	
Phone Number:		Emai	l Address:		
Allergies:		Is th	e patient Diabetic:	Y O NO ICD-10 Code:	
Emergency Contact:		Pho	ne Number:		
Primary Diagnosis: MS - Relapsing RemittingMS - Primary ProgressiveOther:		gressive	Infusion Center - Lab Orders (Check order for Infusion Center to manage): Obtain Quantitative Immunoglobin		
	: 1. List of current Medic diagnosis, 4. Relevant lal		ng Results (surface	ard 3. Clinical progress notes and H&P to support antigen and Core AB)	
Prescribing Physician:		Practi	ce Name:		
Practice Phone: Email:		Off:	ce Fax: Contact:		
Co-managing Physician:		Phone			
		Medication (Order		
New Start: 920 mg/2	eous injection in the	ocrelizumab and 23	,000 units of hy	raluronidase) administered as a single 23 m ninutes every 6 months	
☐ Acetaminon	hen (Tylenol) □ 500 mg □	1 650 mg □ 1000 mg PO	□ Cetirizine (7	Zyrtec) 10mg PO	
☐ Loratadine (Claritin) 10mg PO				amine (Benadryl) □ 25 mg □ 50 mg □ PO □ IV	
☐ Dexamethasone 20mg PO ☐ Other: Dose: Route:					
Adverse Dr	(It is recommended to a	dd an oral corticosteroid and an antih Manage any adverse re	action that may o	antipyretic) occur per approved ADR Protocol.	
			•	esriber's Signature (SIGN BELOW) gent with medical and pharmacy insurance providers.	
Physician's	NPI#	Physician's Address			
Prescriber's	Signature		Da	ate	

Legal Notice: The prescriber is to comply with their state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber. The document(s) accompanying this transmission may contain confidential health information that is legally protected. This information is intended only for the use of the recipient named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless permitted or required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. This prescription may be filled out at a pharmacy of the patient's choice. ©2025 ContinuumRx Services, Inc. All rights reserved.